Survey offers look at life, treatment priorities of those living with ALS

How hope is everywhere when our community gathers

This past Sunday dawned crisp and cool on the eastern shore of Maryland, with a hint of light rain falling from a few clouds dappled against an otherwise vivid blue sky. I dressed to be outdoors, making sure my orange Tim Lowrey Panel T-shirt was visible under my jacket,…

Man with ALS controls devices using brain-computer interface

A man with amyotrophic lateral sclerosis (ALS) was able to control external devices — lighting and a TV — with only his thoughts using a brain-computer interface (BCI) device, according to a recent study. Called Cortical Communication (CortiCom), the BCI system learns to predict a person’s intended action by…

Zydus launches Phase 2 trial of anti-inflammatory ZYIL1

Zydus Lifesciences has launched a Phase 2 clinical trial to evaluate the safety and effectiveness of its experimental anti-inflammatory therapy ZYIL1 in people with amyotrophic lateral sclerosis (ALS). The company announced it has received clearance for the clinical trial (NCT05981040) from India’s Central Drugs Standard Control Organization…

FDA names CB03, aiming to protect neurons, an orphan drug for ALS

The U.S. Food and Drug Administration (FDA) has given orphan drug designation to CB03, Zhimeng Biopharma’s small molecule treatment candidate for amyotrophic lateral sclerosis (ALS). CB03 is designed to bolster nerve cell health by regulating potassium channels on these cells, reducing the hyperexcitability that is damaging to…